Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome

Glauser, Tracy A.; Kluger, Gerhard; Sachdeo, Rǎjesh C.; Krauss, Gregory L.; Perdomo, Carlos; Arroyo, Santiago

doi:10.1212/01.wnl.0000303813.95800.0d

Cited by 319 publications

(420 citation statements)

References 53 publications

Supporting

Mentioning

370

Contrasting

Unclassified

Order By: Relevance

“…Key inclusion criteria for this study were as follows: (a) children and adults ages 2 to 54 years with onset of LGS before [18][19][20] that included patients with characteristics similar to those of patients in the CONTAIN trial (i.e., age range, number of drop seizures, seizures not controlled by previous regimens, use of study drug therapy as adjunctive therapy). Felbamate was excluded, as none of its studies were conducted with patients of characteristics similar to those in the clobazam, rufinamide, topiramate, and lamotrigine trials.…”

mentioning

confidence: 99%

Budget Impact Analysis of Antiepileptic Drugs for Lennox-Gastaut Syndrome

Skornicki¹,

Clements²,

O’Sullivan³

2014

JMCP

View full text Add to dashboard Cite

BACKGROUND: In October 2011, clobazam was FDA-approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a debilitating childhood epilepsy characterized by drop attacks, for patients 2 years and older.OBJECTIVE: To assess the budget impact of adding clobazam to an antiepileptic drug (AED) portfolio containing topiramate, lamotrigine, and rufinamide in a hypothetical, 100,000-member commercially insured health plan.METHODS: Patient characteristics and AED efficacy (decrease in dropseizure frequency) were modeled with clinical data. Medical costs were derived from administrative claims data from a large U.S. managed health plan, with the assumption that 2.3% of drop seizures required medical care. Two-year budget impact was measured. Results were expressed as the overall difference in costs (medical and pharmacy) to a health plan and cost per member per month (PMPM) after addition of clobazam. Analyses of alternative scenarios were performed.RESULTS: With the assumption that 0.04% of the plan population had LGS, adding clobazam to the formulary resulted in cost savings of $98,059 in year 1 and $131,690 in year 2 (savings of $0.08 and $0.11 PMPM, respectively). Analyses of alternative scenarios with lower seizure rates upon discontinuation or greater long-term efficacy for lamotrigine and topiramate did not substantially alter conclusions. The assumption that fewer drop seizures required medical care resulted in a savings of approximately $5,000 per year with clobazam, which suggested that medically attended drop seizures drive costs.CONCLUSIONS: Medically attended drop seizures are a major cost driver for LGS patients. Adding clobazam to a health plan formulary can have a positive overall budget impact through decreased medical costs associated with drop seizures.

show abstract

mentioning

confidence: 99%

Budget Impact Analysis of Antiepileptic Drugs for Lennox-Gastaut Syndrome

Skornicki¹,

Clements²,

O’Sullivan³

2014

JMCP

View full text Add to dashboard Cite

show abstract

“…Glauser et al (2008) принимали участие 138 пациентов с СЛГ в возрасте от 4 до 30 лет. Критерии включения предполагали ча-стоту приступов не менее 90 в месяц до начала терапии руфинамидом.…”

Section: детской неврологииunclassified

“…Получены достоверные различия по частоте дроп-атак, тониче-ских / атонических приступов (p < 0,0001) в группе ру-финамида (средняя редукция частоты -42,5 %) по сравнению с группой плацебо (увеличение часто-ты -1,4 %). В группе руфинамида отмечено значи-тельное уменьшение тяжести приступов (p = 0,0041) и более высокая доля респондеров (уменьшение ча-стоты приступов на 50 % и более) как в отношении частоты всех приступов (p = 0,0045), так и дроп-атак (p = 0,002) [8].…”

Section: детской неврологииunclassified

Rufinamide in the Treatment of Lennox–gastaut Syndrome: Review of Foreign Literature

Мухин¹,

Пылаева²

2015

Rus. ž. det. nevrol.

View full text Add to dashboard Cite

“…15 Patients were between the ages of 4 and 30 years, were treated with 1 to 3 AEDs at baseline, and had at least 90 seizures in the month before study entry. Three end points that were addressed were the percent change in total seizure frequency for 28 days, the percent change in atonic seizure frequency in 28 days, and seizure severity based on apparent parent/guardian global evaluation.…”

Section: Efficacymentioning

confidence: 99%

“…More unique to rufinamide is the potential for cardiac conduction disturbances with QT interval shortening. 14,15 In the placebo-controlled trial, the observed degree of QT shortening was mild; nevertheless, the potential for increased risk of ventricular arrhythmia should be noted. Rufinamide should be avoided in patients with familial short QT syndrome and used with caution in combination with other drugs that shorten QT interval.…”

Section: Adverse Effectsmentioning

confidence: 99%

Antiepileptic Drugs 2012: Recent Advances and Trends

Sirven

Noe

Hoerth

et al. 2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

There are now 24 antiepileptic drugs (AEDs) approved for use in epilepsy in the United States by the Food and Drug Administration. A literature search was conducted using PubMed, MEDLINE, and Google for all English-language articles that discuss newly approved AEDs and the use of AEDs in epilepsy in the United States from January 1, 2008, through December 31, 2011. Five new agents were identified that have come onto the market within the past 2 years. Moreover, 3 trends involving AEDs have become clinically important and must be considered by all who treat patients with epilepsy. These trends include issues of generic substitution of AEDs, pharmacogenomics predicting serious adverse events in certain ethnic populations, and the issue of the suicide risk involving the entire class of AEDs. This article discusses the most recent AEDs approved for use in the United States and the 3 important trends shaping the modern medical management of epilepsy.

show abstract

Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome

Abstract: Rufinamide was an effective and well-tolerated treatment for seizures associated with Lennox-Gastaut syndrome.

Cited by 319 publications

References 53 publications

Budget Impact Analysis of Antiepileptic Drugs for Lennox-Gastaut Syndrome

Budget Impact Analysis of Antiepileptic Drugs for Lennox-Gastaut Syndrome

Rufinamide in the Treatment of Lennox–gastaut Syndrome: Review of Foreign Literature

Antiepileptic Drugs 2012: Recent Advances and Trends

Contact Info

Product

Resources

About